替比夫定辅助治疗对乙型肝炎肝硬化患者血清IL-18、IL-12、IL-37及TNF-α水平的影响

Effect of telbivudine on serum IL-18,IL-12,IL-37 and TNF-α levels in patients with HBV-related hepatocirrhosis

目的探究替比夫定辅助治疗对乙型肝炎肝硬化患者血清白介素-18（interleukin-18,IL-18）、IL-12、IL-37及肿瘤坏死因子α（tumor necrosis factorα,TNF-α）水平影响。方法收集2013年10月~2015年6月迁安市传染病医院肝内科乙型肝炎肝硬化患者66例,根据治疗方法不同分为对照组和治疗组,其中治疗组34例,对照组32例,2组均采用临床乙型肝炎肝硬化常规治疗方案,治疗组在此基础上加用替比夫定辅助治疗,治疗结束后对比分析血清IL-18、IL-12、IL-37、TNF-α水平以及不良反应。结果治疗后2组血清IL-18、IL-12、IL-37及TNF-α水平下降（P〈0.05）。治疗后与对照组相比,治疗组患者血清上述指标水平较低（P〈0.05）。结论替比夫定辅助治疗乙型肝炎肝硬化具有抑制病毒复制,改善肝功能以及免疫反应。

Objective To explore the effect of telbivudine on serum interleukin-18（ IL-18）,IL-12,IL-37 and tumor necrosis factor α（ TNF-α）levels in patients with HBV-related hepatocirrhosis. Methods 66 cases of patients with HBV-related hepatocirrhosis were collected and divided into treatment group and control group according to the different treatment method,34 cases in control group were treated with routine treatment,32 cases in treatment group were treated by telbivudine on the basis of routine treatment. The serum IL-18,IL-12,IL-37,TNF-α levels and adverse reactions were compared post-treatment. Results Compared with control group,the levels of IL-18,IL-12,IL-37 and TNF-α decreased significantly post-treatment（ P〈0. 05）. The above levels were significantly lower in treatment group post-treatment than that in control group（ P〈0. 05）. Conclusion Telbivudine adjuvant therapy could suppress viral replication,and improve liver function and immune response in patients with HBV-related hepatocirrhosis.